Viyash Scientific, through its wholly owned subsidiary Alivira Animal Health, has signed a binding agreement to acquire 100 per cent stake in BioForLife Italia Srl, a leading pet care company based in Milan, Italy.

The acquisition, for a cash consideration of ₹188 crore is expected to close in Q2 FY27.

The transaction represents a significant step in Viyash’s strategy to capitalise on the mega-trend of a growing Companion Animal Health Generics market.

It expands Alivira’s global Companion Animal Health business and strengthens its presence in the European pet care market.

Italy is among the five largest animal health markets in Europe, with companion animal care emerging as its fastest-growing segment driven by rising pet ownership, increasing pet humanisation trends and higher spending on preventive and specialised veterinary care.

BioForLife, based in Milan, Italy, specialises in the development, commercialisation and distribution of pet care products. With a strong product portfolio and pipeline for pet health, BFL has established strong positions in nutritional complements, pharmaceuticals, and rapid diagnostic tests. BFL is also building a business in fast growing segments like dermatology and ophthalmology.

BFL reaches over 80 per cent of all veterinary clinics in Italy, thereby providing well-established customer relationships for future growth.

The acquisition will provide a platform for launching new products from Alivira’s pipeline in Italy, while simultaneously providing opportunities to expand the BFL range to other markets in the Alivira group located in Asia, Europe, West Asia and Latam.

Dr Haribabu Bodeputi, Managing Director and Group CEO, Viyash Scientific said the acquisition represents another important step in the company’s strategy to build a leading global Companion Animal Health business.

BioForLife provides an established platform in Italy, one of Europe’s most attractive pet care markets, while strengthening our presence across the region, he said.

The combination of BioForLife’s commercial reach and Alivira’s product development capabilities creates a compelling opportunity to accelerate growth, he added.

Published on June 8, 2026